Navigation Links
Hope For Those With Pancreatic Cancer

According to researchers the identification of a key molecule that controls the growth, spread and survival of pancreatic cancer cells // could be a promising step toward new and better treatment options for pancreatic cancer .

Researchers say they have discovered what role the GSK-3 Beta molecule plays in pancreatic cancer and that they have found the molecule is critical in pancreatic cancer cell growth and survival through its effect on NF Kappa B -- a well-known cancer cell gene regulator.

According to the study, the finding gives researchers a new way to target the key pancreatic cancer-promoting molecules with smaller molecules to inhibit their action. Researchers also believe the finding can lead to a method to make pancreatic cancer cells more receptive to gemcitabine, the only drug currently available for the disease.

Thus in conclusion researchers say their finding holds promise, for the development of new strategies to help fight other types of cancer.
'"/>




Page: 1

Related medicine news :

1. Identifying Those At Risk For Diabetes
2. Identifying Those At Risk For Diabetes
3. Good News For Those Suffering From Excessive Sweating
4. Good News For Those Of You Suffering From Rheumatoid Arthritis
5. Cell Implants May Help Those Who Suffer From Parkinsons
6. Firms Told To Employ Those With Aspergers Syndrome
7. Statins Prescribed To Those Who Are At a Risk Of Developing A Heart Disease
8. Adventure Enthusiasts, Risk Takers and Those Living on the Edge, Good News Coming Your Way
9. Number of Allergic Anaphylaxis Episodes Are Far More Than Those Recorded
10. Korea: No Discrimination against Those with AIDS/HIV in the Workplace
11. Free Herceptin Treatment for Those Who Live Over the Welsh Border
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hope For Those With Pancreatic Cancer

Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 1Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 2Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 1Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 1United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 3